Aurinia Pharmaceuticals reports Q3 EPS 23c, consensus 16c

Reports Q3 revenue $73.5M, consensus $67.7M. “LUPKYNIS sales experienced continued momentum following last year’s update to the American College of Rheumatology lupus nephritis treatment guidelines, which recommend the incorporation of drugs like LUPKYNIS into first-line therapy in order to preserve kidney function,” stated Peter Greenleaf, President and Chief Executive Officer of Aurinia. “Additionally, we are excited about the positive results from our Phase 1 study of aritinercept, a dual inhibitor of B cell-activating factor and a proliferation-inducing ligand and look forward to initiating clinical studies in two autoimmune diseases by the end of this year.”